- Home
- KF vs NTHI Comparison
KF vs NTHI Comparison
Compare KF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KF | NTHI |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 178.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KF | NTHI |
|---|---|---|
| Price | $43.72 | $7.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.6K | 27.3K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.15 | $3.20 |
| 52 Week High | $58.59 | $15.50 |
Technical Indicators
Market Signals| Indicator | KF | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 33.09 |
| Support Level | $31.38 | $6.40 |
| Resistance Level | $49.38 | $7.70 |
| Average True Range (ATR) | 1.89 | 0.73 |
| MACD | -0.68 | -0.15 |
| Stochastic Oscillator | 21.19 | 5.32 |
Price Performance
Historical ComparisonAbout KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).